Tag: bipolar I disorder

FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder

by Lucy Parsons | Jun 2, 2021 | News | 0

Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021

Read More

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999